BEAM-302 Extends Human Base-Editing Biomarker Data

Evidence Company presentation · Data Cutoff June 24, 2026 · Discovery September 8, 2026 · Importance 5/5 · Direction Positive Summary Beam Therapeutics presented updated Phase I/II data for BEAM-302, an LNP-delivered adenine base editor intended to correct the SERPINA1 PiZ mutation in alpha-1 antitrypsin…